225 related articles for article (PubMed ID: 35267616)
1. The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies.
Colmenares R; Álvarez N; Barrio S; Martínez-López J; Ayala R
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267616
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsies and minimal residual disease in lymphoid malignancies.
Bou Zerdan M; Kassab J; Saba L; Haroun E; Bou Zerdan M; Allam S; Nasr L; Macaron W; Mammadli M; Abou Moussa S; Chaulagain CP
Front Oncol; 2023; 13():1173701. PubMed ID: 37228488
[TBL] [Abstract][Full Text] [Related]
3. Cell-free DNA - Minimally invasive marker of hematological malignancies.
Kubaczkova V; Vrabel D; Sedlarikova L; Besse L; Sevcikova S
Eur J Haematol; 2017 Oct; 99(4):291-299. PubMed ID: 28692178
[TBL] [Abstract][Full Text] [Related]
4. Liquid biopsies and minimal residual disease in myeloid malignancies.
Allam S; Nasr K; Khalid F; Shah Z; Khan Suheb MZ; Mulla S; Vikash S; Bou Zerdan M; Anwer F; Chaulagain CP
Front Oncol; 2023; 13():1164017. PubMed ID: 37213280
[TBL] [Abstract][Full Text] [Related]
5. Identification of Immunoglobulin Gene Rearrangement Biomarkers in Multiple Myeloma through cfDNA-Based Liquid Biopsy Using tchDNA-Seq.
Buenache N; Sánchez-delaCruz A; Cuenca I; Giménez A; Moreno L; Martínez-López J; Rosa-Rosa JM
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296872
[TBL] [Abstract][Full Text] [Related]
6. Genetic Profiling of Cell-Free DNA in Liquid Biopsies: A Complementary Tool for the Diagnosis of B-Cell Lymphomas and the Surveillance of Measurable Residual Disease.
Figaredo G; Martín-Muñoz A; Barrio S; Parrilla L; Campos-Martín Y; Poza M; Rufián L; Algara P; De La Torre M; Jiménez Ubieto A; Martínez-López J; Casado LF; Mollejo M
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627050
[TBL] [Abstract][Full Text] [Related]
7. Cell-free DNA for genomic profiling and minimal residual disease monitoring in Myeloma- are we there yet?
Thakral D; Das N; Basnal A; Gupta R
Am J Blood Res; 2020; 10(3):26-45. PubMed ID: 32685257
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy.
Ferla V; Antonini E; Perini T; Farina F; Masottini S; Malato S; Marktel S; Lupo Stanghellini MT; Tresoldi C; Ciceri F; Marcatti M
Front Oncol; 2022; 12():932852. PubMed ID: 36052251
[TBL] [Abstract][Full Text] [Related]
9. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
10. Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia.
Della Starza I; De Novi LA; Elia L; Bellomarino V; Beldinanzi M; Soscia R; Cardinali D; Chiaretti S; Guarini A; Foà R
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672325
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
Waldschmidt JM; Anand P; Knoechel B; Lohr JG
Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of Circulating Cell-Free DNA Detection in Multiple Myeloma: A Meta-Analysis.
Ye X; Li W; Zhang L; Yu J
Front Oncol; 2022; 12():852573. PubMed ID: 35252019
[TBL] [Abstract][Full Text] [Related]
13. Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges.
Riva G; Nasillo V; Ottomano AM; Bergonzini G; Paolini A; Forghieri F; Lusenti B; Barozzi P; Lagreca I; Fiorcari S; Martinelli S; Maffei R; Marasca R; Potenza L; Comoli P; Manfredini R; Tagliafico E; Trenti T; Luppi M
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572809
[TBL] [Abstract][Full Text] [Related]
14. New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies.
Dogliotti I; Drandi D; Genuardi E; Ferrero S
J Clin Med; 2018 Sep; 7(9):. PubMed ID: 30231510
[TBL] [Abstract][Full Text] [Related]
15. "Friends and foes" of multiple myeloma measurable/minimal residual disease evaluation by next generation flow.
Pacelli P; Raspadori D; Bestoso E; Gozzetti A; Bocchia M
Front Oncol; 2022; 12():1057713. PubMed ID: 36518304
[TBL] [Abstract][Full Text] [Related]
16. Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis.
Ntanasis-Stathopoulos I; Gavriatopoulou M; Terpos E; Fotiou D; Kastritis E; Dimopoulos MA
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e905-e909. PubMed ID: 32723621
[TBL] [Abstract][Full Text] [Related]
17. Real-Time Molecular Monitoring in Acute Myeloid Leukemia With Circulating Tumor DNA.
Thakral D; Gupta R; Sahoo RK; Verma P; Kumar I; Vashishtha S
Front Cell Dev Biol; 2020; 8():604391. PubMed ID: 33363162
[TBL] [Abstract][Full Text] [Related]
18. Liquid Biopsies for Monitoring Medulloblastoma: Circulating Tumor DNA as a Biomarker for Disease Progression and Treatment Response.
Buccilli B; Rodriguez Molina MA; Redrovan Palomeque DP; Herrera Sabán CA; C Caliwag FM; Contreras Flores CJS; Abeysiriwardana CWJ; Diarte E; Arruarana VS; Calderon Martinez E
Cureus; 2024 Jan; 16(1):e51712. PubMed ID: 38313884
[TBL] [Abstract][Full Text] [Related]
19. Measurable residual disease in multiple myeloma and in acute myeloid leukemia, an evolving topic.
Castelli G; Pelosi E; Testa U
Ann Ist Super Sanita; 2021; 57(4):300-313. PubMed ID: 35076420
[TBL] [Abstract][Full Text] [Related]
20. ClonoSEQ assay for the detection of lymphoid malignancies.
Monter A; Nomdedéu JF
Expert Rev Mol Diagn; 2019 Jul; 19(7):571-578. PubMed ID: 31179776
[No Abstract] [Full Text] [Related]
[Next] [New Search]
